Edgewise Therapeutics, Inc. EWTX Other Nonoperating Income
Other Nonoperating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncome.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s other nonoperating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s other nonoperating income?
- Edgewise Therapeutics, Inc. (EWTX) reported other nonoperating income of $5.1M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s other nonoperating income changed year-over-year?
- Edgewise Therapeutics, Inc.'s other nonoperating income decreased by 1.1% year-over-year, from $5.16M to $5.1M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s other nonoperating income?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s other nonoperating income has grown at a 176.8% compound annual growth rate (CAGR), from $402K to $23.61M.
- What does other nonoperating income mean?
- This metric represents income generated from activities outside of the company's core clinical-stage biopharmaceutical operations, such as interest earned on cash balances or investment income. It provides insight into the company's ability to supplement its primary funding sources through treasury management and non-core financial activities. Monitoring this helps investors understand how much non-operating cash flow offsets the high burn rate typical of drug development.